Source : EuropeanMarkets
Ulf Mark Schneider, CEO of Fresenius, said:
“Our strong growth trend continued with double-digit constant currency sales and earnings growth in the first nine months. All business segments contributed to the excellent financial results. Fresenius Kabi in particular stood out, benefiting from drug shortages and new product launches in the U.S. market. We raise our Group earnings guidance for 2015 and remain optimistic about the positive fundamentals in our markets.”
Financial Highlights
Q3/2015:
Sales €6.9 billion (+16% at actual rates, +7% in constant currency)
EBIT €1,027 million (+25% at actual rates, +12% in constant currency)
Net income €367 million (+31% at actual rates, +20% in constant currency)
Q1-3/2015:
Sales €20.4 billion (+22% at actual rates, +11% in constant currency)
EBIT €2.8 billion (+28% at actual rates, +14% in constant currency)
Net income €1,009 million (+31% at actual rates, +19% in constant currency)
2015 Group earnings guidance raised
Based on the Group’s excellent financial results in the first nine months of 2015 and strong prospects for the remainder of the year, Fresenius raises its 2015 Group earnings guidance. Net income is now expected to grow by 20% to 22% in constant currency. Previously, Fresenius expected net income growth of 18% to 21% in constant currency. The company fully confirms its Group sales guidance. Sales are expected to increase by 8% to 10% in constant currency.
The net debt/EBITDA ratio is now expected to be below 3.0 at the end of 2015. Previously, Fresenius expected the ratio to be approximately 3.0.
Source : Press Release Fresenius SE & Co KGaA, Bad Homburg v.d. H. (Germany), 29 October, 2015
